Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation - Wikidata - awgldk - TriplyDB

Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation

Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation

http://www.wikidata.org/entity/Q37316471

about

Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia Phosphoinositide 3-kinase: friend and foe in cardiovascular disease No contribution of IP3-R(2) to disease phenotype in models of dilated cardiomyopathy or pressure overload hypertrophy.Protein Kinases as Drug Development Targets for Heart Disease Therapy Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current.Norepinephrine-Induced Adrenergic Activation Strikingly Increased the Atrial Fibrillation Duration through β1- and α1-Adrenergic Receptor-Mediated Signaling in Mice.Phosphoinositide 3-kinase (PI3K(p110alpha)) directly regulates key components of the Z-disc and cardiac structure.Deletion of PDK1 causes cardiac sodium current reduction in mice Prolonged action potential duration in cardiac ablation of PDK1 mice Cardiac-specific deletion of the microtubule-binding protein CENP-F causes dilated cardiomyopathy Cancer Therapy Targeting the HER2-PI3K Pathway: Potential Impact on the Heart.Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function Inhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure Overload Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism Pharmacogenetics of Potassium Channel Blockers.Cardiac aging and insulin resistance: could insulin/insulin-like growth factor (IGF) signaling be used as a therapeutic target?An introduction to murine models of atrial fibrillation Therapeutic applications of PI3K inhibitors in cardiovascular diseases.Effect of catheter ablation on progression of paroxysmal atrial fibrillation.Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation.Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.Arrhythmic complications of tyrosine kinase inhibitors.Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.Gene Array Analyzer: alternative usage of gene arrays to study alternative splicing events The role of PI3Kα isoform in cardioprotection.Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease.Research advances in kinase enzymes and inhibitors for cardiovascular disease treatment.Impact of Renal Denervation on Atrial Arrhythmogenic Substrate in Ischemic Model of Heart Failure.Rhodiola Inhibits Atrial Arrhythmogenesis in a Heart Failure Model.Sex differences in response to miRNA-34a therapy in mouse models of cardiac disease: identification of sex-, disease- and treatment-regulated miRNAs.Understanding Key Mechanisms of Exercise-Induced Cardiac Protection to Mitigate Disease: Current Knowledge and Emerging Concepts.Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.Inhibition of the α-Subunit of Phosphoinositide 3-Kinase in Heart Increases Late Sodium Current and Is Arrhythmogenic.The IGF1-PI3K-Akt Signaling Pathway in Mediating Exercise-Induced Cardiac Hypertrophy and Protection.Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3K-Akt-eNOS pathways in spontaneously hypertensive rats.Enhanced phosphoinositide 3-kinase(p110α) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes.The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice.

P2860

Q26738946-4FED2E80-5D37-4B5D-9A93-B5EF228FD0C1 Q26765624-19D25039-C9CC-4926-9993-0CF8B459FF91 Q26796228-CFADC05D-34B5-4450-8641-DC26872C3ED8 Q33641690-F5534E73-63F5-4B25-9444-36A287C4174C Q33678033-93396F82-0C83-4170-BD91-E0B6568801DF Q33911355-B034AFCD-1F77-4B6F-9071-88AEDD13513C Q34486523-25C1E1A7-C8A9-434E-9920-12B3ACD312A3 Q35182995-C10637E9-5152-4162-916F-FF7BAF4C7075 Q35188267-3AE8FD06-5CE8-4EED-83A7-F500C25A5F78 Q35791798-E19EF49F-6BD3-455E-9767-45641E3BB86C Q36051051-D02F7465-C255-4212-9EB2-373C18235B4A Q36061754-D5DEF82C-7502-4474-98D9-FA53F68C217B Q36378477-03FCA103-2524-4833-B067-FAB48914825A Q36634367-0A24F3BA-F92A-4DCE-A9A9-04B9A10F8CA7 Q36771317-4472F142-B42A-49FC-ADD3-C1EC31942DB3 Q36970927-987037DB-04F5-4106-82C0-42AF775ACC35 Q37442678-1A74A5D7-31EF-4873-A91E-D06A1D67D0DF Q38039083-5FC7C235-D852-4FD4-A1DE-B68CC3E0343E Q38089742-C51B2B04-A84E-476B-BAD6-B67DE686F61D Q38427159-4BCFA62A-8867-4C3E-963E-53D43EB02080 Q38815946-C93D0F10-6B20-4F06-A7B8-A975BEEF893E Q38944823-D7212457-B142-4C54-9242-6FEE01B88E73 Q38978097-305039AE-0A7C-4873-A006-97FB395E7FF8 Q39154824-B133CC1D-20E4-4D29-94CD-1C452746D45B Q39325783-0166601F-D087-45C1-97A0-864641377F90 Q39383524-07681B09-129E-44CB-81FA-BC45AE65FC77 Q39436207-041105F8-B0D0-4467-AF86-DE20B4B1DB62 Q42683501-43A53AE6-6B8A-41E1-AE8E-92D158C7A9F8 Q45289568-CFF172A2-4BFC-482D-B237-5F518380DEFD Q47121794-D0BB3193-1EEA-4F80-8ECA-B1C487EB8DCA Q47649543-5B13602A-837E-4733-970A-FA705C939CEB Q48053517-628DA293-CCCD-44EC-A15E-0ABE65BF2035 Q48211539-D82FFC6E-8DA1-4E6C-BF59-8340EDA7CA1D Q49917356-7593E38A-482B-41D3-B941-C3EAADE5FC06 Q50121608-E4DFBD58-B5C6-4BC8-BFE3-9E867ED83B34 Q52644018-5B922AB9-0BC0-4714-8E69-79440F190F22 Q54139767-EFDFF3C1-0771-4379-A612-DD97DB10B6E9 Q54260332-418759F6-9DC9-4553-AD46-8AC2F61FEB4E Q54481875-98D0DD5D-6DF4-4E20-9C90-C591FBB9C202 Q55069411-6E686F7F-8DA7-4970-91EA-BCD78374797F

P2860

Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation

http://www.wikidata.org/entity/Q37316471

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Reduced phosphoinositide 3-kin ...... ibility to atrial fibrillation

@en

Reduced phosphoinositide 3-kinase

@nl

type

label

Reduced phosphoinositide 3-kin ...... ibility to atrial fibrillation

@en

Reduced phosphoinositide 3-kinase

@nl

prefLabel

Reduced phosphoinositide 3-kin ...... ibility to atrial fibrillation

@en

Reduced phosphoinositide 3-kinase

@nl

P1433

Q37316471-75042600-8929-4A29-955E-A3AC51D30517

P1476

Q37316471-9D1CEEF0-FBD0-4C36-80F3-AEBD5557DF88

P2093

Q37316471-04CBB375-03CC-4BE6-B9BF-4B4DD3209A51

Q37316471-05889827-FC2B-400E-AA9E-A05D9BDE33C6

Q37316471-3685DB2B-47C6-4E44-84F4-770F3A0F4014

Q37316471-45F21397-334A-4914-AAEB-B7AA1F091E88

Q37316471-48EC4CB9-2657-4274-B9D5-D2794639F12F

Q37316471-793D9E90-4479-4847-8BAC-CD48819BC27E

Q37316471-7982BC21-F062-424C-AABC-48E9111567E5

Q37316471-7EA9AFB7-78F8-4805-8685-DEFB269F7AA7

Q37316471-9D198F41-FD98-46E7-A9DE-A05779B68991

Q37316471-A974F521-A53E-4EC8-A9F5-175BA9B178E8

P2860

Q37316471-000603AF-2924-436A-8054-D4B2971A5B29

Q37316471-0172DD57-3E00-4356-8202-5C7F4B1AD947

Q37316471-155F2326-0C50-46EE-8816-22C19AE919F3

Q37316471-180CB655-6FC9-428B-BB3E-ECB9A757EDA3

Q37316471-24985B5D-7DCC-4174-805A-4D77DF0A8555

Q37316471-2A7A080F-C974-4447-9D39-FA7AAEF290BE

Q37316471-2C0F9979-894E-451D-8BD9-03EFE58BBFAD

Q37316471-32D1C273-0675-4EFC-89AF-9650A9F8F7AA

Q37316471-38930637-32CA-42FD-8DB3-5EFC1F18C61B

Q37316471-3B25566E-844E-49DD-A686-1D0C168DC981

P304

Q37316471-5F0C62E3-1F2F-4863-ADF9-14686BEB86D6

P31

Q37316471-300A07B1-DA94-448B-9647-69154BE6D719

P356

Q37316471-4D5BC3D4-A862-4B2D-8CA7-A0F32E80DFA2

P407

Q37316471-323BA6E3-E7CF-413A-8C58-96A585B30ACC

P433

Q37316471-69EBB6F7-06C0-4F47-A8D6-381B8ED0CB05

P478

Q37316471-2D8DDC36-B8FC-4976-AD33-BD1BE4B17C94

P50

Q37316471-57BBBD85-5E24-470B-AFDE-190D6FC5644C

Q37316471-58F968BD-E457-4074-866E-D137FE5352A9

Q37316471-691A0F1D-F1B3-43F5-B0FF-BCF0BAF5968F

Q37316471-6D9D4672-8809-4876-B6E3-78AFAFB18151

Q37316471-C5AFCF2E-DD99-43F0-BB46-E3B351201E4B

Q37316471-CCFFE267-8E17-42B2-A8B0-9224DAEAFA1B

P577

Q37316471-194D2216-01A8-4277-A541-B1DFC5AE66D8

P5875

Q37316471-A0AC8785-1C3D-4546-BD25-F139425E99DC

P698

Q37316471-604B44C7-2B07-4069-ABD5-50288F3E81B4

P921

Q37316471-43C18C0A-A667-48F8-84DE-6AC29AF1D278

P932

Q37316471-536642C9-2219-4959-9E47-B1BFEB530E97

P356

AJPATH.2009.090126

P1433

The American Journal of Pathology

P1476

Reduced phosphoinositide 3-kin ...... ibility to atrial fibrillation

@en

P2093

Elizabeth A Woodcock

http://www.w3.org/2001/XMLSchema#string

Helen Kiriazis

http://www.w3.org/2001/XMLSchema#string

Joon Win Tan

http://www.w3.org/2001/XMLSchema#string

Julie R McMullen

http://www.w3.org/2001/XMLSchema#string

Nelly Cemerlang

http://www.w3.org/2001/XMLSchema#string

Robert L Medcalf

http://www.w3.org/2001/XMLSchema#string

Ruby C Y Lin

http://www.w3.org/2001/XMLSchema#string

Seigo Izumo

http://www.w3.org/2001/XMLSchema#string

Silvana Marasco

http://www.w3.org/2001/XMLSchema#string

Tetsuo Shioi

http://www.w3.org/2001/XMLSchema#string

P2860

MURC, a muscle-restricted coiled-coil protein that modulates the Rho/ROCK pathway, induces cardiac dysfunction and conduction disturbance

Mutation in nuclear pore component NUP155 leads to atrial fibrillation and early sudden cardiac death

Obesity and insulin resistance

Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration

Inhibition of basic leucine zipper transcription is a major mediator of atrial dilatation

Atrial fibrillation in KCNE1-null mice

Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation

Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction.

Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure.

ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Co

P304

998-1009

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2353/AJPATH.2009.090126

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

175

http://www.w3.org/2001/XMLSchema#string

P50

Geoffrey A. Head

Garry L Jennings

Junichi Sadoshima

Lynette Pretorius

Elena V Lukoshkova

P577

2009-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26741166

http://www.w3.org/2001/XMLSchema#string

P698

19679877

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation

P932

2731119

http://www.w3.org/2001/XMLSchema#string